• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Personal Stories
    • Newsletter
  • About Pompe
  • Blog
  • Links
  • Connections
Select Page
Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

by Brad Crittenden | Feb 25, 2019 | News

Amicus Therapeutics announced today that they have received Breakthrough Therapy Designation (BTD) for their AT-GAA treatment for Pompe disease.

Recent Posts

  • Audentes Therapeutics’ “Be Bold for Courageous Patients” Program to Support Patients Living with Rare Diseases
  • Amicus Therapeutics establishes a 75,000 sq. ft. Gene Therapy Center of Excellence
  • Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment
  • Rare Disease Day 2019
  • Sarepta Therapeutics Enters into a Strategic Relationship with Aldevron in Support of Their Gene Therapy Program
  • Terms
  • Privacy

Copyright © 2006 - 2019 Canadian Association of Pompe | Developed by PacificByte